PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and tolerability study of its ketamine patch, KETARX, in minipigs. 

KETARX consists of hydrogel-forming microneedle arrays and an accompanying reservoir that can significantly increase the amount of drug permeating through the skin. The system aims at empowering patients to dose their medication remotely in a safe manner without the need to attend to a healthcare center, and future plans include incorporating anti-tampering and anti-abuse features.

In this completed stage, KETARX has demonstrated its ability to deliver ketamine over 40 hours. The system offers flexible dosing through increased size and drug load or concentration to better align with its administration methods available: intravenous injection, intradermal microneedle patch, and subcutaneous pump.  

KETARX was manufactured by PharmaTher’s partner LTS LOHMANN Therapie-Systeme AG, while the study was done …

Full story available on